Top Industry Leaders in the Cone Rod Dystrophy Market
Beacon Therapeutics Secures $120 Million Funding for Gene Therapy Development: Beacon Therapeutics, a UK-based company, received $120 million in funding to develop gene therapies for retinal diseases, including CRD. This investment will support the clinical development of their lead candidate, BEACON-RPE, which targets the RPE65 gene mutation responsible for a form of CRD.
MeiraGTx Initiates Phase 1/2 Trial for Retinal Gene Therapy: MeiraGTx, a US-based company, began a Phase 1/2 clinical trial evaluating their MGT009 gene therapy for the treatment of Leber's congenital amaurosis (LCA), a form of CRD. This trial represents a significant step forward in developing gene therapy for CRD patients.
Spark Therapeutics Announces Positive Phase 3 Data for Gene Therapy: Spark Therapeutics, a US-based company, reported positive results from their Phase 3 trial of SPARC64, a gene therapy for LCA. These results suggest that SPARC64 could potentially offer a one-time treatment option for LCA patients, including those with CRD.
List of Cone-Rod Dystrophy Key Companies in the Market
- GlaxoSmithKline Plc. (U.S.)
- Johnson & Johnson (U.S.)
- Sanofi (Switzerland)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Abbott Laboratories (U.S.)
- Sunovion Pharmaceuticals (U.S.)
- Cephalon (U.S.)
- DSM (India)
- Amway (U.S.)
- Vitamin Shoppe (U.S.)
- Intas Pharmaceutials Limited (India)
- Sun Pharmaceuticals Ltd. (India)
- Emcure Pharmaceuticals Limited (India)
- Nutrilite (U.S.)
- NutraScience Labs (U.S.)
